RAF1 and skin neoplasm: The enhanced ERK1/2 activation in RAF-wild-type cells means that ∼20% of patients treated with vemurafenib or dabrafenib develop non-metastatic skin tumours [85,86], pre-malignant colonic adenomas and gastric polyps after RAF inhibitor treatment [87].